Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Policy / Regulatory

NMPA Implements Regulatory Reforms for Drug and Medical Device Industries

Fineline Cube Jan 17, 2025

The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...

Company Deals Drug

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

Fineline Cube Jan 17, 2025

Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...

Policy / Regulatory

NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance

Fineline Cube Jan 17, 2025

The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...

Company Deals

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Fineline Cube Jan 17, 2025

Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...

Company Drug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Fineline Cube Jan 17, 2025

China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...

Company

Siemens Lays Foundation for New Medical Equipment Base in Shenzhen

Fineline Cube Jan 17, 2025

Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...

Company Deals

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Fineline Cube Jan 17, 2025

China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...

Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Company Deals

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Fineline Cube Jan 17, 2025

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...

Company Medical Device

Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results

Fineline Cube Jan 17, 2025

US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...

Company Drug

Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials

Fineline Cube Jan 17, 2025

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...

Company Drug

Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial

Fineline Cube Jan 17, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...

Company Drug

Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials

Fineline Cube Jan 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...

Company Drug

CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials

Fineline Cube Jan 17, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...

Company Drug

Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment

Fineline Cube Jan 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...

Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Company Deals

GE Healthcare and Sutter Health Form $1B Care Alliance

Fineline Cube Jan 16, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...

Posts pagination

1 … 219 220 221 … 660

Recent updates

  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.